Department of Surgery, Kansai Medical University, Hirakata, Osaka ; Department of Internal Medicine, Seiko Hospital, Neyagawa, Osaka.
Onco Targets Ther. 2012;5:185-9. doi: 10.2147/OTT.S36515. Epub 2012 Sep 17.
Brain metastases from breast cancer occur in 20%-40% of patients, and the frequency has increased over time. New radiosensitizers and cytotoxic or cytostatic agents, and innovative techniques of drug delivery are still under investigation.
Five patients with brain metastases who did not respond to whole-brain radiotherapy and then received bevacizumab combined with paclitaxel were identified using our database of records between 2011 and 2012. The clinicopathological data and outcomes for these patients were then reviewed.
The median time to disease progression was 86 days. Of five patients, two (40%) achieved a partial response, two had stable disease, and one had progressive disease. In addition, one patient with brain metastases had ptosis and diplopia due to metastases of the right extraocular muscles. However, not only the brain metastases, but also the ptosis and diplopia began to disappear after 1 month of treatment. The most common treatment-related adverse events (all grades) were hypertension (60%), neuropathy (40%), and proteinuria (20%). No grade 3 toxicity was seen. No intracranial hemorrhage was observed.
We present five patients with breast cancer and brain metastases, with benefits from systemic chemotherapy when combined with bevacizumab.
乳腺癌脑转移的发生率为 20%-40%，且这一比例随时间推移而增加。新的放射增敏剂、细胞毒性或细胞抑制剂以及创新的药物输送技术仍在研究中。
通过我们 2011 年至 2012 年的病历数据库，发现了 5 例接受全脑放疗后未缓解且随后接受贝伐珠单抗联合紫杉醇治疗的脑转移患者。回顾了这些患者的临床病理数据和结局。
疾病进展的中位时间为 86 天。5 例患者中，2 例（40%）达到部分缓解，2 例疾病稳定，1 例疾病进展。此外，1 例脑转移患者因右侧眼外肌转移而出现上睑下垂和复视。但不仅脑转移，而且上睑下垂和复视在治疗 1 个月后开始消失。最常见的治疗相关不良事件（所有级别）为高血压（60%）、神经病变（40%）和蛋白尿（20%）。未观察到 3 级毒性。未发生颅内出血。
我们报告了 5 例乳腺癌脑转移患者，接受贝伐珠单抗联合系统化疗后获益。
